AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method for screening an individual or group of patients for the likelihood of having left ventricular systolic dysfunction (LVSD) comprising, in any order the steps of:

(a) measurement of the levels of a biomarker in a sample or samples of bodily fluid of said patient; and

(b) conducting an electrocardiography (ECG) measurement on said patient or group of individuals;

identification of the presence or absence of one or more major abnormality factors from the ECG trace;

assigning or calculating weighting factors for (a) and (b); and

obtaining a result indicative of the probability of said individual having LVSD.

2. (Currently Amended) [[A]] The method ~~as claimed in~~ of claim 1, comprising the further step performed in any order in relation to the steps of claim 1 of identification of the presence or absence of one or more cofactors which are known to be risk factors for CVD; and assigning or calculating a weighing factor (c) to obtain said result.

3. (Currently Amended) [[A]] The method ~~according to~~ of claim 1 [[or 2]], wherein the weighting factors for (a), (b) and/or (c) are derived by logistic regression analysis on measurements of a biomarker, ECG findings, and of one or more cofactors which are known to be risk factors for CVD; wherein the patient population is taken from the general population and individuals have no previous diagnosis of LVSD.

4. (Currently Amended) [[A]] The method ~~according to any of claims~~ of claim 1 [[to 3]], wherein the biomarker is a natriuretic peptide.

5. (Currently Amended) [[A]] The method ~~according to~~ of claim 2, ~~or any claim dependent thereon~~, wherein one or more cofactors are selected from myocardial infarction (MI) and angina.

6. (Currently Amended) An algorithm for the determination of the likelihood of an individual of having left ventricular systolic dysfunction (LVSD) according to the following formula:

$$\text{Log}_e\ p/(1-p) = \text{Constant}+B_1*(y) + B_2*(\text{ECG abnormality, a}) + B_3*(\text{history of MI or angina, a})$$

where p is the probability of having heart failure as defined by LVSD;

B_1, B_2, and B_3 are the coefficients for the logistic model for predicting LVSD;

~~Wherein~~ wherein 'a' is a factor to indicate the presence or absence of ECG abnormality and history of myocardial infarction (MI) or angina and wherein 'a' refers to any two numbers sufficiently separated as to impart a different weighting on the coefficients B_2 and B_3 in the presence or absence of ECG abnormality and history of MI or angina[[.]];

'y' is either $\log_{10}$ natriuretic peptide expressed in pM, or peptide centile;

wherein peptide centile, expressed as per cent, is determined by ranking all biomarker levels determined by measuring the biomarker level for an apparently healthy population using a chosen assay kit and expressing them as percentiles.

7. (Currently Amended) An algorithm for the determination of the likelihood of an individual of having left ventricular systolic dysfunction (LVSD) according to the following formula:

$$\text{Log}_e\ p/(1-p) = \text{Constant}+B_1*(y) + B_2*(\text{ECG abnormality, a})$$

where p is the probability of having heart failure due to LVSD

B_1 and B_2 are the coefficients for the logistic model for predicting LVSD;

~~Wherein~~ wherein 'a' is a factor to indicate the presence or absence of ECG abnormality and wherein 'a' refers to any two numbers sufficiently separated as to impart a different weighting on the coefficient B_2 in the presence or absence of ECG abnormality[[.]];

'y' is either $\log_{10}$ natriuretic peptide expressed in pM, or peptide centile;

wherein peptide centile, expressed as per cent, is determined by ranking all biomarker levels determined by measuring the biomarker level for an apparently healthy population using a chosen assay kit and expressing them as percentiles.

8. (Currently Amended) [[A]] The method ~~as claimed in any~~ of ~~claims~~ claim 1 [[to 5]], in which the identification of the presence or absence of one or more major abnormality factors from the ECG trace is determined from the QRS, QT, and/or JT interval.

9. (Currently Amended) [[A]] The method ~~as claimed in~~ of claim 8, in which the identification of the major abnormality factor is determined from the ratio QRS interval/QT interval or QRS interval/JT interval.

10. (Currently Amended) A method of deriving an indicator of heart failure in a patient comprising:
measuring as a first factor the level of a cardiac bio-marker in a sample of bodily fluid of said patient;
obtaining a patient electrocardiography (ECG) trace;
identifying as a second factor the presence of absence of one or more abnormality factors from the ECG trace; and
deriving an indicator of heart failure as a function of the first and second factors.

11. (Currently Amended) [[A]] The method ~~as claimed in~~ of claim 10, wherein the cardiac bio-marker is a marker indicative of the presence or absence of heart failure.

12. (Currently Amended) [[A]] The method ~~as claimed in~~ of claim 11, in which the marker is a natriuretic peptide.

13. (Currently Amended) [[A]] The method ~~as claimed in~~ of claim 12, in which the natriuretic peptide is BNP.

14. (Currently Amended) [[A]] The method ~~as claimed in any~~ of ~~claims~~ claim 10 [[to 13]], for deriving an indicator of LVSD.

15. (Currently Amended) A method of deriving an indicator of heart failure in a patient comprising:
obtaining a patient electrocardiography (ECG);
measuring at least one of the QRS, QT and JT interval from the ECG and deriving the indicator of heart failure from the the QRS, JT and/or QT interval.

16. (Currently Amended) [[A]] The method ~~as claimed in~~ of claim 15, in which the indicator is derived as a function of the ratio QRS interval/QT interval or QRS interval/JT interval.

17. (Currently Amended) [[A]] The method ~~as claimed in claims~~ of claim 15 [[or 16]], further comprising measuring the level of a bio-marker in a sample of bodily fluid of a patient and deriving the indicator as a function in addition of the measured level.

18. (Original) An apparatus for measuring an indicator of heart failure in a patient comprising at least one of a QRS interval detector, a QT interval detector and a JT interval detector.

19. (Currently Amended) A heart failure indicator apparatus comprising a data processor arranged to receive data representative of the measurement of a level of a bio-marker in a sample of bodily fluid of a patient and data representing an electrocardiography (ECG) measurement on the patient and/or data representing a measurement of at least one of a QRS or a QT or a JT interval in an ECG, the processor being further arranged to process the received data to derive an indicator of heart failure.

20. (Currently Amended) A kit of parts comprising at least one of a detector for detecting as a factor levels of a bio-marker in a sample of bodily fluid of a patient, a detector for obtaining an electrocardiography (ECG) trace from on a patient, a processor for identifying as a factor the presence or absence of one or more major abnormality factors from the ECG

trace; a processor for measuring as a factor at least one of the QRS, QT and JT interval from an ECG trace and a processor for processing measurements to derive an indicator of heart failure as a function of one or more of the factors.

21. (Currently Amended) A computer program comprising a set of instructions configured to implement a method as claimed in ~~any of claims~~ claim 1 ~~to 5 or 8 to 17~~.

22. (Original) A computer configured to implement a computer program as claimed in claim 21.

23. (Original) A computer readable medium storing a computer program as claimed in claim 21.